SkinHealth Systems Q3 revenue beats estimates
Overview
US medical aesthetics firm's Q3 revenue fell yr/yr but beat analyst expectations
Q3 adjusted EBITDA beat analyst expectations, reflecting improved operational efficiency
Company retired its 2026 debt as planned
Outlook
Company sees 2026 net sales of $281 mln to $287 mln
Company expects 2026 adjusted EBITDA of $48 mln to $50 mln
Result Drivers
CONSUMABLES GROWTH - Co said consumables sales returned to growth in Q3
GROSS MARGIN IMPROVEMENT - Co attributed higher gross margin to lower inventory charges and tariff-related recoveries
LOWER OPERATING EXPENSES - Co said reduced personnel and professional fees drove lower operating expenses
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Beat | $69.20 mln | $67.78 mln (9 Analysts) |
Q3 Net Loss | $900,000 | ||
Q3 Adjusted EBITDA | Beat | $13.40 mln | $6.02 mln (9 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the personal products peer group is "buy."
Wall Street's median 12-month price target for Skinhealth Systems Inc is $12.50, about 13.1% above its November 4 closing price of $11.05
Reuters Recommended Reads
Nov 4 - Coty tops estimates on prestige brands boost amid turnaround
Nov 4 - Estee Lauder sets 2030 growth, margin targets as turnaround advances
Nov 5 - Elf sees Q2 sales boost with marketing, Europe expansion
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)